Pharmalicensings Latest Report Reveals New Early Stage Dealmaking Trends



With deals increasing in terms of number and value, partnering at early stage development is now an integral component of pharmaceutical and biotech business strategy. Deal complexity has advanced in financial reward structures and exchange of non-monetary capabilities.

To follow this interest in early stage dealmaking, Pharmalicensing has revised and updated its successful Early Stage and Discovery Deals report. The new report analyzes early stage dealmaking trends and discusses the basics of dealmaking structures, covering payments terms and deal valuations. Updated with in-depth contracts, case studies and new deal data the report reflects the present status of early stage dealmaking.

The report includes an updated section of today'ss early stage deal strategies and structures, featuring an extensive collection of supporting case studies from 2006, which bring into focus the current methods employed by companies to achieve the best deal.

A full data analysis of early stage deal terms and trends in the final section of the report breaks down the headline values of deals allowing readers to gain an insight into individual payments and rates.

For more information on 'sEarly Stage and Discovery Deals: Strategy, Structure and Payment Terms 2nd Edition's or other reports, go to store.pharmalicensing.com or contact the reports team on tel: +44 1904 520460 or email: sales @ pharmalicensing.com

Pharmalicensing Ltd (pharmalicensing.com), based in York, UK, is the leading online global resource for partnering, licensing and business development within the life science and biopharmaceutical industry.

Contact: Johan Ohlsson, Strategic Analyst, Business Development (johan.ohlsson @ pharmalicensing.com; Tel +44 1904 520491)





Pharmalicensings Latest Report Reveals New Early Stage Dealmaking Trends